Low-dose interleukin-2 in patients with mild to moderate Alzheimer’s disease: a randomized clinical trial

Low-dose interleukin-2 in patients with mild to moderate Alzheimer’s disease: a randomized clinical trial

Abstract Background We previously documented that regulatory T cells (Tregs) immunomodulatory mechanisms are compromised in Alzheimer’s disease (AD), shifting the immune system toward a pro-inflammatory response. However, Tregs are a potentially restorable therapeutic target in AD. In this study, we...

Full description

Saved in:
Bibliographic Details
Main Authors: Alireza Faridar, Nazaret Gamez, Daling Li, Yanling Wang, Reena Boradia, Aaron D. Thome, Weihua Zhao, David R. Beers, Jason R. Thonhoff, Mohammad O. Nakawah, Gustavo C. Román, John J. Volpi, Jon B. Toledo, Michael George, Charles S. Davis, Belen Pascual, Michael Grundman, Joseph C. Masdeu, Stanley H. Appel
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Alzheimer’s Research & Therapy
Subjects:
Alzheimer’s Disease
Inflammation
Immunotherapy
Clinical trial
Treg
Immune system
Online Access:https://doi.org/10.1186/s13195-025-01791-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13195-025-01791-x

Similar Items